HU0202119D0 - - Google Patents

Info

Publication number
HU0202119D0
HU0202119D0 HU0202119A HUP0202119A HU0202119D0 HU 0202119 D0 HU0202119 D0 HU 0202119D0 HU 0202119 A HU0202119 A HU 0202119A HU P0202119 A HUP0202119 A HU P0202119A HU 0202119 D0 HU0202119 D0 HU 0202119D0
Authority
HU
Hungary
Application number
HU0202119A
Other languages
Hungarian (hu)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HU0202119D0 publication Critical patent/HU0202119D0/hu
Publication of HUP0202119A2 publication Critical patent/HUP0202119A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU0202119A 2001-06-29 2002-06-28 OCIF-ot és poliszacharidot tartalmazó komplex HUP0202119A2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001198985 2001-06-29

Publications (2)

Publication Number Publication Date
HU0202119D0 true HU0202119D0 (enExample) 2002-08-28
HUP0202119A2 HUP0202119A2 (hu) 2003-04-28

Family

ID=19036337

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202119A HUP0202119A2 (hu) 2001-06-29 2002-06-28 OCIF-ot és poliszacharidot tartalmazó komplex

Country Status (22)

Country Link
US (3) US20030045456A1 (enExample)
EP (1) EP1270015A3 (enExample)
KR (1) KR20030003124A (enExample)
CN (1) CN1442201A (enExample)
AR (1) AR034716A1 (enExample)
AU (1) AU783126B2 (enExample)
BR (1) BR0202439A (enExample)
CA (1) CA2392383A1 (enExample)
CO (1) CO5390084A1 (enExample)
CZ (1) CZ20022231A3 (enExample)
HK (1) HK1048762A1 (enExample)
HU (1) HUP0202119A2 (enExample)
IL (1) IL150448A0 (enExample)
MX (1) MXPA02006511A (enExample)
NO (1) NO20023144L (enExample)
PA (1) PA8549401A1 (enExample)
PE (1) PE20030254A1 (enExample)
PL (1) PL354799A1 (enExample)
RU (1) RU2232594C2 (enExample)
SG (1) SG98059A1 (enExample)
SK (1) SK9492002A3 (enExample)
ZA (1) ZA200205164B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
PL347559A1 (en) 1998-10-28 2002-04-08 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
WO2003074084A1 (en) * 2002-03-01 2003-09-12 Sankyo Company, Limited A pharmaceutical composition
CN1658895A (zh) 2002-04-10 2005-08-24 应用研究系统Ars股份公司 护骨素在治疗和/或预防纤维变性疾病中的应用
US7585840B2 (en) * 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
RU2323227C2 (ru) * 2003-03-24 2008-04-27 Санкио Компани Лимитед Полимерные модификаторы и фармацевтические композиции
KR100840830B1 (ko) * 2006-09-03 2008-06-23 재단법인서울대학교산학협력재단 고분자 히알루론산을 포함하는 골흡수 저해용 조성물
RU2370271C2 (ru) * 2006-11-22 2009-10-20 Государственное учреждение гематологический научный центр Российской академии медицинских наук (ГУ ГНЦ РАМН) Способ обнаружения комплексов между гепаринами и поликатионами
ITMI20121316A1 (it) * 2012-07-27 2014-01-28 Altergon Sa Complessi di condroitina ad assorbimento transcutaneo
CN115594776B (zh) * 2022-09-19 2024-03-15 山东大学 一种ROS响应性聚合物Mal-PHB-Dextran及细胞背包载药系统

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US139325A (en) * 1873-05-27 Improvement in carriage-springs
US45456A (en) * 1864-12-13 Improved apparatus for carbureting air
US216297A (en) * 1879-06-10 Improvement in ironing-stands
US4207A (en) * 1845-09-27 lewis
US31725A (en) * 1861-03-19 Improvement in cultivators
US181418A (en) * 1876-08-22 Improvement in gas apparatus
TW318142B (enExample) * 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
JP4268684B2 (ja) * 1997-09-24 2009-05-27 第一三共株式会社 骨代謝異常症の診断方法
AU4061899A (en) * 1998-06-15 2000-01-05 Takeda Chemical Industries Ltd. Thienodipyridine derivatives, production and use thereof
PL347559A1 (en) * 1998-10-28 2002-04-08 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
AU6788900A (en) * 1999-09-03 2001-04-10 Amgen, Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
IL155097A0 (en) * 2000-09-28 2003-10-31 Nanocyte Inc Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
WO2003074084A1 (en) * 2002-03-01 2003-09-12 Sankyo Company, Limited A pharmaceutical composition

Also Published As

Publication number Publication date
CO5390084A1 (es) 2004-04-30
IL150448A0 (en) 2002-12-01
US20030045456A1 (en) 2003-03-06
AU783126B2 (en) 2005-09-29
CZ20022231A3 (cs) 2003-02-12
AR034716A1 (es) 2004-03-17
HUP0202119A2 (hu) 2003-04-28
EP1270015A2 (en) 2003-01-02
NO20023144L (no) 2002-12-30
NO20023144D0 (no) 2002-06-28
AU5071902A (en) 2003-01-02
CN1442201A (zh) 2003-09-17
HK1048762A1 (en) 2003-04-17
SG98059A1 (en) 2003-08-20
US20060084595A1 (en) 2006-04-20
RU2232594C2 (ru) 2004-07-20
ZA200205164B (en) 2003-03-24
SK9492002A3 (en) 2003-02-04
PE20030254A1 (es) 2003-03-19
RU2002117385A (ru) 2004-01-27
PL354799A1 (en) 2002-12-30
BR0202439A (pt) 2003-06-10
CA2392383A1 (en) 2002-12-29
MXPA02006511A (es) 2004-08-11
EP1270015A3 (en) 2004-02-25
PA8549401A1 (es) 2003-07-28
US20030139325A1 (en) 2003-07-24
KR20030003124A (ko) 2003-01-09

Similar Documents

Publication Publication Date Title
BE2022C531I2 (enExample)
BE2022C547I2 (enExample)
BE2017C059I2 (enExample)
BE2017C055I2 (enExample)
BE2017C051I2 (enExample)
BE2017C032I2 (enExample)
BE2016C051I2 (enExample)
BE2015C077I2 (enExample)
BE2014C052I2 (enExample)
BE2014C036I2 (enExample)
BE2014C026I2 (enExample)
BE2007C047I2 (enExample)
AU2002307149A8 (enExample)
BE2011C034I2 (enExample)
BE2014C006I2 (enExample)
BRPI0209186B1 (enExample)
BE2017C050I2 (enExample)
BRPI0204884A2 (enExample)
CH1379220H1 (enExample)
BE2014C008I2 (enExample)
BE2016C021I2 (enExample)
BRPI0101486B8 (enExample)
BE2012C051I2 (enExample)
HU0202119D0 (enExample)
BRPI0210463A2 (enExample)

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees